Examinando por Autor "Pellicer-Valero, Óscar J."

Mostrando 1 - 2 de 2

DNA Salivary Methylation Levels of the ACE2 Promoter Are Not Related to ACE2 (rs2285666 and rs2074192), TMPRSS2 (rs12329760 and rs2070788) and ACE1 rs1799752 Polymorphisms in COVID-19 Survivors with Post-COVID-19 Condition
(MDPI, 2025-02-27) Fernández-de-las-Peñas, César; Díaz-Gil, Gema; Gil-Crujera, Antonio; Gómez-Sánchez, Stella Maris; Ambite-Quesada, Silvia; Torres-Macho, Juan; Ryan-Murua, Pablo; Franco-Moreno, Ana; Pellicer-Valero, Óscar J.; Arendt-Nielsen, Lars
El artículo publicado en la revista International Journal of Molecular Sciences (IJMS), aborda una cuestión de gran actualidad científica: la interacción entre factores genéticos y epigenéticos en la persistencia de síntomas post-COVID-19. La revista IJMS, editada por MDPI, está indexada en Journal Citation Reports (JCR) y Scopus, y cuenta con un factor de impacto de 5.6 en su edición más reciente (2024), situándose en el primer cuartil (Q1) en las categorías de Bioquímica y Biología Molecular. Además, presenta un CiteScore de 6.4 en Scopus, lo que refleja su consolidada reputación en el ámbito de las ciencias biomédicas y su alta visibilidad internacional. Este estudio, con una muestra de 279 pacientes previamente hospitalizados por COVID-19, analiza si existe una relación entre los niveles de metilación del promotor del gen ACE2 y cinco polimorfismos genéticos asociados a la infección por SARS-CoV-2. A través de técnicas avanzadas de pirosecuenciación y genotipado, los autores concluyen que no se observa una asociación significativa entre los perfiles epigenéticos y los genotipos analizados, lo que contribuye a delimitar el papel de estos mecanismos en el desarrollo del síndrome post-COVID. La publicación en una revista de alto impacto, con revisión por pares y posicionamiento Q1, avala la calidad metodológica, el rigor científico y la relevancia clínica del trabajo, cumpliendo con los estándares de excelencia requeridos por ANECA para la evaluación de méritos investigadores.
Post-COVID-19 Pain Is Not Associated with DNA Methylation Levels of the ACE2 Promoter in COVID-19 Survivors Hospitalized Due to SARS-CoV-2 Infection
(MDPI, 2024-07-25) Fernández-de-las-Peñas, César; Díaz-Gil, Gema; Gil-Crujera, Antonio; Gómez-Sánchez, Stella Maris; Ambite-Quesda, Silvia; Franco-Moreno, Anabel; Ryan-Murua, Pablo; Torres-Macho, Juan; Pellicer-Valero, Óscar J.; Arendt-Nielsen, Lars; Giordano, Rocco
One of theories explaining the development of long-lasting symptoms after an acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection include changes in the methylation pattern of the host. The current study aimed to investigate whether DNA methylation levels associated with the angiotensin-converting enzyme 2 (ACE2) promoter are different when comparing individuals previously hospitalized due to COVID-19 who then developed long-lasting post-COVID pain with those previously hospitalized due to COVID-19 who did not develop post-COVID-19 pain symptoms. Non-stimulated saliva samples were obtained from a cohort of 279 (mean age: 56.5, SD: 13.0 years old, 51.5% male) COVID-19 survivors who needed hospitalization. Clinical data were collected from hospital medical records. Participants were asked to disclose pain symptoms developed during the first three months after hospital admission due to COVID-19 and persisting at the time of the interview. Methylations of five CpG dinucleotides in the ACE2 promoter were quantified (as percentages). Participants were evaluated up to 17.8 (SD: 5.3) months after hospitalization. Thus, 39.1% of patients exhibited post-COVID-19 pain. Most patients (77.05%) in the cohort developed localized post-COVID-19 pain. Headache and pain in the lower extremity were experienced by 29.4% of the patients. Seven patients received a post-infection diagnosis of fibromyalgia based on the presence of widespread pain characteristics (11.6%) and other associated symptoms. No significant differences in methylation percentages at any CpG location of the ACE2 promoter were identified when comparing individuals with and without post-COVID-19 pain. The current study did not observe differences in methylation levels of the ACE2 promoter depending on the presence or absence of long-lasting post-COVID-19 pain symptoms in individuals who needed hospitalization due to COVID-19 during the first wave of the pandemic.